CONSTANT LEVERAGE LONG - UCB Stock

Certificat

FZ7MB

FRBNPP067HD0

Market Closed - Euronext Paris 10:18:22 2023-12-21 EST
8.745 ^EUR	-7.36%

1 month

+77.78%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB : spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN)	06-28	PU
UCB : Financial Reporting Document	06-26	PU
UCB : Financial Reporting Document	06-26	PU
UCB : epilepsy drug BRIVIACT(brivaracetam) approved in Japan for treatment of focal onset seizures	06-26	PU

More news

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	UCB
Issuer	BNP Paribas
	FZ7MB
ISIN	FRBNPP067HD0
Date issued	2023-11-21
Maturity	Unlimited
Parity	1 : 1
Emission price	5 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	11.99 €
Lowest since issue	4.212 €
Spread	0.47 €
Spread %	5.26%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company